Pulmonary Fibrosis
Conditions
Brief summary
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation between the most prevalent fibrotic interstitial lung diseases. The value of eNose as biomarker for disease progression and response to treatment is also assessed. Besides, validity of several questionnaires for pulmonary fibrosis is investigated.
Detailed description
Patients will be included in the study after signing written informed consent. eNose measurements will take place before or after a routine outpatient clinic visit at the same location as the regular visit, ensuring minimal inconvenience for patients. First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal. After the measurement, patients will complete a short survey about questions relevant for the data analysis (food intake in the last two hours, smoking history, medication use, comorbidities, and symptoms of respiratory infection). In addition, patients will complete the L-PF questionnaire and the Global Rating of Change scale (GRoC). The L-PF questionnaire consists of 21 questions on a 5-point Likert scale about the impact of pulmonary fibrosis on quality of life, and takes about 3 minutes to complete. The GRoC consists of one question on a scale from -7 to 7: were there any changes in your quality of life since your last visit? Symptoms (cough and dyspnea) will be scored on a 10 cm VAS scale from -5 to 5. Next to eNose measurements, demographic data and physiological parameters of patients will be collected from the medical records at baseline, month 6, and month 12. Parameters such as age, gender, diagnosis, time since diagnosis, comorbidities, medication, pulmonary function (forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO)), laboratory parameters (i.e. auto-immune antibodies), HRCT pattern, BAL results and if applicable also genetic mutations, will be recorded and stored in an electronic case report form. These parameters will be collected as part of routine daily care, patients will not undergo any additional tests for study purposes. HRCT scans will be re-analysed centrally by an experienced ILD thoracic radiologist. Mortality and lung function parameters will also be collected at 24 months, if this information is available.
Interventions
DIAGNOSTIC_TESTElectronic nose
First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
Sponsors
Erasmus Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of fibrotic ILD, as discussed in a multidisciplinary team meeting (50% incident patients and 50% prevalent patients). Patients are classified as 'incident' if they received a diagnosed in a multidisciplinary team meeting within the past six months. Patients will be required to have fibrosis on a HRCT scan \<1 year before enrollment in the study defined as reticular abnormality with traction bronchiectasis, with or without honeycombing, as determined by a radiologist. No minimum extent of fibrosis will be required.
Exclusion criteria
* Alcohol consumption ≤ 12 hours before the measurement * Physically not able to perform eNose measurement
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Therapeutic effect | 6 months after start therapy | Relating start of anti-fibrotic medication to change in eNose values |
| Worsening of respiratory symptoms (cough and/or dyspnea) | 12 months after inclusion | Worsening of respiratory symptoms (cough and/or dyspnea) measured on a visual analogue scale (0-10, 0 no symptoms, 10 most severe symptoms) |
| Mortality | 12 months after inclusion | Deceased subjects |
| Diagnostic accuracy for IPF - CHP | Baseline | Accuracy for differentiating IPF from CHP |
| AUC for IPF - CHP | Baseline | AUC for differentiating IPF from CHP |
| AUC for IPF - iNSIP | Baseline | AUC for differentiating IPF from iNSIP |
| Diagnostic accuracy for IPF - iNSIP | Baseline | Accuracy for differentiating IPF from iNSIP |
| AUC for IPF - IPAF | Baseline | AUC for differentiating IPF from IPAF |
| Diagnostic accuracy for IPF - IPAF | Baseline | Accuracy for differentiating IPF from IPAF |
| Diagnostic accuracy for IPF - CTD-ILD | Baseline | Accuracy for differentiating IPF from CTD-ILD |
| AUC for IPF - CTD-ILD | Baseline | AUC for differentiating IPF from CTD-ILD |
| Diagnostic accuracy for IPF - unclassifiable ILD | Baseline | Accuracy for differentiating IPF from unclassifiable ILD |
| AUC for IPF - unclassifiable ILD | Baseline | AUC for differentiating IPF from unclassifiable ILD |
| Diagnostic accuracy for CHP - iNSIP | Baseline | Accuracy for differentiating CHP from iNSIP |
| AUC for CHP - iNSIP | Baseline | AUC for differentiating CHP from iNSIP |
| Diagnostic accuracy for CHP - IPAF | Baseline | Accuracy for differentiating CHP from IPAF |
| AUC for CHP - IPAF | Baseline | AUC for differentiating CHP from IPAF |
| Diagnostic accuracy for CHP - CTD-ILD | Baseline | Accuracy for differentiating CHP from CTD-ILD |
| AUC for CHP - CTD-ILD | Baseline | AUC for differentiating CHP from CTD-ILD |
| Diagnostic accuracy for CHP - unclassifiable ILD | Baseline | Accuracy for differentiating CHP from unclassifiable ILD |
| AUC for CHP - unclassifiable ILD | Baseline | AUC for differentiating CHP from unclassifiable ILD |
| Diagnostic accuracy for iNSIP - IPAF | Baseline | Accuracy for differentiating iNSIP from IPAF |
| AUC for iNSIP - IPAF | Baseline | AUC for differentiating iNSIP from IPAF |
| Diagnostic accuracy for iNSIP - CTD-ILD | Baseline | Accuracy for differentiating iNSIP from CTD-ILD |
| AUC for iNSIP - CTD-ILD | Baseline | AUC for differentiating iNSIP from CTD-ILD |
| Diagnostic accuracy for iNSIP - unclassifiable ILD | Baseline | Accuracy for differentiating iNSIP from unclassifiable ILD |
| AUC for iNSIP - unclassifiable ILD | Baseline | AUC for differentiating iNSIP from unclassifiable ILD |
| Diagnostic accuracy for IPAF - CTD-ILD | Baseline | Accuracy for differentiating IPAF from CTD-ILD |
| AUC for IPAF - CTD-ILD | Baseline | AUC for differentiating IPAF from CTD-ILD |
| Diagnostic accuracy for IPAF - unclassifiable ILD | Baseline | Accuracy for differentiating IPAF from unclassifiable ILD |
| AUC for IPAF - unclassifiable ILD | Baseline | AUC for differentiating IPAF from unclassifiable ILD |
| Diagnostic accuracy for CTD-ILD - unclassifiable ILD | Baseline | Accuracy for differentiating CTD-ILD from unclassifiable ILD |
| AUC for CTD-ILD - unclassifiable ILD | Baseline | AUC for differentiating CTD-ILD from unclassifiable ILD |
| Disease progression | 12 months after inclusion | FVC decline in combination with worsening of respiratory symptoms (cough and/or dyspnea) and/or progressive fibrosis on CT scan |
| Diagnostic accuracy of disease progression | 6 months after inclusion | Relating disease progression (based on FVC decline, CT scan and/or symptoms) to change in eNose values |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GRoC evaluation | 6 months after inclusion | Relating Longitudinal changes in score of Global Rating of Change Scale to eNose values |
| L-PF evaluation | 6 months after inclusion | Relating Longitudinal changes in score of L-PF questionnaire to eNose values |
Countries
Australia, France, Germany, Netherlands, United Kingdom
Outcome results
None listed